iFAST Diagnostics funding news – London-based iFAST Diagnostics Raises Over €5.9 Million  in Seed Funding

Rapid, Life-Saving Technology

iFAST's technology quickly analyzes thousands of bacteria on a microchip providing fast and accurate results. This aligns with the NHS’s goal to fight antimicrobial resistance within five years helping improve patient care and strengthen healthcare systems against drug-resistant infections.

Read also - Oriole Networks funding news – London-based Oriole Networks Secures an Additional €20.2 Million Funding

Toby King, CEO of iFAST, said: “We are incredibly excited to receive the investment we need to bring our technology to market just a couple of years after founding the company. The thought of saving patients’ lives by having the correct antibiotic at the right time is hugely motivating for the whole team. I’d like to thank all our existing investors for continuing to support us, and KHP in particular for leading the round, as well as EInk, RAW, and OKG for having the conviction to come on board at this pivotal time for our business.”

Tim Irish, Partner at KHP Ventures, highlighted the importance of iFAST’s technology: “iFAST is ideally placed to tackle the ever-increasing global threat of antimicrobial resistance. The technology is 10x faster than the current gold standard for AST while maintaining the same levels of accuracy, throughput, and cost. We are excited to partner with iFAST and concurrently help the NHS achieve its 5-year plan to combat antimicrobial resistance.”

Richard Haycock, CEO of Qantx, praised the company’s achievements and potential impact: “We are proud to continue our support for iFAST Diagnostics as they build technology to transform the way clinicians identify and treat antibiotic-resistant infections. The amazing progress the team has made in the last 18 months is a testament to their hard work, and we’re excited to see their solution be made available to hospitals in the UK, Europe, and the US with this investment.”

A Key Step in Solving Healthcare Challenges

With antimicrobial resistance being a serious global health issue, iFAST's AST platform provides a solution that could greatly improve patient care and health outcomes around the world.

With the new funding, iFAST Diagnostics aims to advance its mission to fight antimicrobial resistance. The company is developing a groundbreaking antimicrobial susceptibility test (AST) that delivers results in under three hours, a big improvement over the current 48-72 hour wait.

About iFAST

iFAST is developing a game-changing, rapid antimicrobial susceptibility test, that will enable every patient with bacterial infections to receive the right antibiotic, on time, every time. Currently, these tests take 48-72 hours, but iFAST's tests are 10x faster - giving full quantitative and qualitative results in under 3 hours from a positive blood culture or bacterial isolate.